- WEBINAR -
GMP Radiolabeling Development.

From First Discussion to Method Transfer.

GMP Radiolabeling Development.

From First Discussion to Method Transfer.

Turning Radiolabeling into reliable, GMP-ready analytical methods.

Radiolabeling is a critical step in radiopharmaceutical development.
Small deviations in chemistry, analytics or process control can impact product quality, delay validation and complicate regulatory approval.

In this webinar, we walk you through a real-world development journey – from first discussion to validated analytical methods and routine GMP quality control, ready for transfer to CDMO or manufacturing.

  • Date: 21 April 2026
  • Time: 15:00 - 16:00 CET
  • Format: Online via Teams
Free of charge.

Why radiolabeling development

becomes a bottleneck.

Radiopharmaceutical development requires more than successful labeling.
Methods must be analytically robust, GMP-compliant and suitable for routine quality control.

Typical challenges in radiolabeling projects:

  • Unstable or insufficiently controlled labeling processes
  • Analytical methods not suitable for GMP environments
  • Delays in validation and regulatory readiness
  • Inefficient transfer to CDMO or production
  • Disconnect between development, analytics and QC

From development complexity

to GMP-ready methods.

A structured, analytical-driven approach enables:


  • Early definition of robust radiolabeling strategies
  • Develop analytical methods fit for purpose
  • Efficient validation under GMP conditions
  • Reliable implementation in routine quality control

The result:
Faster development timelines, reduced risk and reliable product release.

What you will learn

in this webinar:

Real-world development insights.

Delivered by leading experts.

Erlend Myrnes
Director CMC Development
at Actithera

Erlend is a cross-functional team leader & coach with almost 10 years of experience from different roles in CMC development, manufacturing & supply of small molecule & antibody-based radiopharmaceuticals from pre-clinical, to early and late-stage clinical stages.

Dirk Freitag-Stechl
Managing Director
at CUP contract labs

Dirk is an expert in pharmaceutical analytics and GMP-regulated environments. He has extensive experience in building high-performance laboratory structures and supporting complex development projects from early phase to routine quality control.

Falco Reissig
Head of Analytical Chemistry
at CUP contract labs

Falco has a strong focus on radiolabeling, radiopharmacy and nuclear medicine. His expertise includes method development, validation, and transfer in GMP environments, particularly for complex and high-risk pharmaceutical projects

Konstantina Makrypidi
Research Scientist
at CUP contract labs

Konstantina specializes in analytical method development and optimization. She is closely involved in translating early-stage research into robust, validated methods suitable for GMP environments and routine application.

EXPERT VOICES

Radiolabeling only becomes valuable when methods are robust enough to support validation, transfer and routine GMP quality control.

Erlend Myrnes, Director CMC Development at Actithera

Why CUP contract labs?

CUP Contract Labs combines deep analytical expertise with GMP-compliant laboratory infrastructure.

Our approach:

  • Integrated development and analytical expertise
  • Strong focus on GMP applicability
  • Experience in complex radiopharmaceutical projects
  • Methods designed for real-world implementation

Join the webinar.

And learn more about GMP Radiolabeling Development.

We are very much looking forward to welcoming you!

Gain practical insight into how radiolabeling development can be translated into validated GMP methods and reliable quality control.

See you at 21 April 2026 at 3pm.